A novel germline mutation in Peroxisome Proliferator-Activated Receptor γ gene associated with large intestine polyp formation and dyslipidemia

被引:19
作者
Capaccio, D. [1 ,3 ]
Ciccodicola, A. [2 ]
Sabatino, L. [1 ,3 ]
Casamassimi, A. [2 ]
Pancione, M. [1 ]
Fucci, A. [1 ]
Febbraro, A. [4 ]
Merlino, A. [5 ]
Graziano, G. [1 ]
Colantuoni, V. [1 ,3 ]
机构
[1] Univ Sannio, Dept Biol & Environm Sci, I-82100 Benevento, Italy
[2] A Buzzati Traverso CNR, Inst Genet & Biophys, I-80131 Naples, Italy
[3] Univ Naples Federico II, Dept Biochem & Med Biotechnol, I-80131 Naples, Italy
[4] Fatebenefratelli Hosp, Div Med Oncol, I-82100 Benevento, Italy
[5] Univ Naples Federico II, Dept Chem, I-80100 Naples, Italy
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2010年 / 1802卷 / 06期
关键词
Peroxisome Proliferator-Activated Receptor; Loss-of-function mutation; Colorectal cancer; Dyslipidemia; DOMINANT-NEGATIVE MUTATIONS; PPAR-GAMMA; NUCLEAR RECEPTORS; CRYSTAL-STRUCTURE; EXPRESSION; MACROPHAGES; PROGRESSION; REGULATOR; REVEALS; LESSONS;
D O I
10.1016/j.bbadis.2010.01.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We report a novel PPARG germline mutation in a patient affected by colorectal cancer that replaces serine 289 with cysteine in the mature protein (S289C). The mutant has impaired transactivation potential and acts as dominant negative to the wild type receptor. In addition, it no longer restrains cell proliferation both in vitro and in vivo. Interestingly, the S289C mutant poorly activates target genes and interferes with the inflammatory pathway in tumor tissues and proximal normal mucosa. Consistently, only mutation carriers exhibit colonic lesions that can evolve to dysplastic polyps. The proband presented also dyslipidemia, hypertension and overweight, not associated to type 2 diabetes: of note, family members tested positive for the mutation and display only a dyslipidemic profile at variable penetrance with other biochemical parameters in the normal range. Finally, superimposing the mutation to the crystal structure of the ligand binding domain, the new Cys289 becomes so closely positioned to Cys285 to form an S-S bridge. This would reduce the depth of the ligand binding pocket and impede agonist positioning, explaining the biological effects and subcellular distribution of the mutant protein. This is the first PPARG germline mutation associated with dyslipidemia and colonic polyp formation that can progress to full-blown adenocarcinoma. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:572 / 581
页数:10
相关论文
共 38 条
[21]   A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ [J].
Pascual, G ;
Fong, AL ;
Ogawa, S ;
Gamliel, A ;
Li, AC ;
Perissi, V ;
Rose, DW ;
Willson, TM ;
Rosenfeld, MG ;
Glass, CK .
NATURE, 2005, 437 (7059) :759-763
[22]   Amino acid neighbours and detailed conformational analysis of cysteines in proteins [J].
Petersen, MTN ;
Jonson, PH ;
Petersen, SB .
PROTEIN ENGINEERING, 1999, 12 (07) :535-548
[23]   REGULATION OF G(1) PROGRESSION BY E2A AND ID HELIX-LOOP-HELIX PROTEINS [J].
PEVERALI, FA ;
RAMQVIST, T ;
SAFFRICH, R ;
PEPPERKOK, R ;
BARONE, MV ;
PHILIPSON, L .
EMBO JOURNAL, 1994, 13 (18) :4291-4301
[24]   Mucosal macrophages and the regulation of immune responses in the intestine [J].
Platt, Andrew M. ;
Mowat, Allan Mcl. .
IMMUNOLOGY LETTERS, 2008, 119 (1-2) :22-31
[25]   Obesity associated with a mutation in a genetic regulator of adipocyte differentiation [J].
Ristow, M ;
Müller-Wieland, D ;
Pfeiffer, A ;
Krone, W ;
Kahn, CR .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (14) :953-959
[26]   Significance of anti-inflammatory effects of PPARγ agonists? [J].
Rogler, G. .
GUT, 2006, 55 (08) :1067-1069
[27]   Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma [J].
Russell-Swetek, A. ;
West, A. N. ;
Mintern, J. E. ;
Jenkins, J. ;
Rodriguez-Galindo, C. ;
Ribeiro, R. ;
Zambetti, G. P. .
JOURNAL OF MEDICAL GENETICS, 2008, 45 (09) :603-606
[28]   A novel peroxisome proliferator-activated receptor γ isoform with dominant negative activity generated by alternative splicing [J].
Sabatino, L ;
Casamassimi, A ;
Peluso, G ;
Barone, MV ;
Capaccio, D ;
Migliore, C ;
Bonelli, P ;
Pedicini, A ;
Febbraro, A ;
Ciccodicola, A ;
Colantuoni, V .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (28) :26517-26525
[29]   Loss-of-function mutations in PPARγ associated with human colon cancer [J].
Sarraf, P ;
Mueller, E ;
Smith, WM ;
Wright, HM ;
Kum, JB ;
Aaltonen, LA ;
de la Chapelle, A ;
Spiegelman, BM ;
Eng, C .
MOLECULAR CELL, 1999, 3 (06) :799-804
[30]   Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-γ [J].
Savage, DB ;
Tan, GD ;
Acerini, CL ;
Jebb, SA ;
Agostini, M ;
Gurnell, M ;
Williams, RL ;
Umpleby, AM ;
Thomas, EL ;
Bell, JD ;
Dixon, AK ;
Dunne, F ;
Boiani, R ;
Cinti, S ;
Vidal-Puig, A ;
Karpe, F ;
Chatterjee, VKK ;
Rahilly, S .
DIABETES, 2003, 52 (04) :910-917